15600 Federal Register / Vol. 89, No. 43 / Monday, March 4, 2024 / Notices 

response. In vitro and in vivo 

experiments demonstrate that this 

nanoparticle platform has the potential 

for use as a robust SARS–CoV–2 

vaccine. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404, as well as for further 

development and evaluation under a 

research collaboration. 

Potential Commercial Applications: 

• Novel SARS–CoV–2 vaccine and 

universal vaccines against coronavirus 

• Vaccine development against other 

viral pathogens such as HIV and flu 

Competitive Advantages: 

• Higher potency, potentially longer 

protection compared to other SARS– 

CoV–2 vaccine formulations. 

• Potent immune response via genetic 

delivery, including DNA and RNA 

immunization. 

• Improved immunogenicity 

compared to other nanoparticle or viruslike-particle (VLP)-based vaccines for 

SARS–CoV–2 spike protein. 

Development Stage: 

• Pre-Clinical. 

Inventors: Drs. John Mascola, Cuiping 

Liu, Wei Shi, Amarendra Pegu, Lingshu 

Wang, Wing-Pui Kong, all of NIAID. 

Publication: Liu, C., Wang, L., 

Merriam, J.S. et al. Self-assembling 

SARS–CoV–2 spike-HBsAg 

nanoparticles elicit potent and durable 

neutralizing antibody responses via 

genetic delivery. npj Vaccines 8, 111 

(2023). https://doi.org/10.1038/s41541- 

023-00707-w. 

Intellectual Property: HHS Reference 

No. E–171–2021–0–EIR–00 U.S. Patent 

Application No. 63/278,956 filed on 

November 12, 2021; HHS Reference No. 

E–171–2021–0–EIR–00 U.S. Patent 

Application No WO 2023/086961; PCT/ 

US2022/079750, filed on November 11, 

2022. 

Licensing Contact: To license this 

technology, please contact Brian Bailey, 

Ph.D.; 240–669–5128 or 301–201–9217; 

bbailey@mail.nih.gov, and reference E– 

171–2021. 

Collaborative Research Opportunity: 

The National Institute of Allergy and 

Infectious Diseases is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize this technology. Areas of 

specific interest include (a) testing 

developability of the antibodies elicited 

by SARS–CoV–2 spike-HBsAg 

nanoparticles (e.g., biophysical 

characteristics, cross-reactivity, 

pharmacokinetics, toxicity), (b) preclinical model assessment, and (c) 

human clinical trials. For collaboration 

opportunities, please contact Brian 

Bailey, Ph.D.; 240–669–5128 or 301– 

201–9217, bbailey@mail.nih.gov. 

Dated: February 15, 2024. 

Surekha Vathyam, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2024–04423 Filed 3–1–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Fellowships: Physiology and Pathobiology of 

Cardiovascular and Respiratory Systems: 

Cardiovascular. 

Date: March 21–22, 2024. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Michael L. Bloom, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6187, 

MSC 7804, Bethesda, MD 20892, 301–451– 

0132, bloomm2@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Topics in Microbial and Host 

Interactions. 

Date: March 21, 2024. 

Time: 10:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Jui Pandhare, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 594–7735, pandharej2@

csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Atherosclerosis and Vascular Inflammation. 

Date: March 21, 2024. 

Time: 11:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Natalia Komissarova, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5207, 

MSC 7846, Bethesda, MD 20892, 301–435– 

1206, komissar@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Population and Public Health 

Approaches in HIV/AIDS. 

Date: March 22, 2024. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Elia E. Ortenberg, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3108, 

Bethesda, MD 20892, 301–827–7189, 

femiaee@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Molecular Genetics and Genomics. 

Date: March 22, 2024. 

Time: 1:00 p.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Brian Paul Chadwick, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 594–3586, chadwickbp@

csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Cell, Structure and Function-1. 

Date: March 22, 2024. 

Time: 1:00 p.m. to 6:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Anne Marie Strohecker, 

Ph.D., Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge Drive, 

Bethesda, MD 20892, (301) 867–5309, 

stroheckeram@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; RFA–RM– 

23–013: Partnerships with Common Fund 

Data Ecosystem Resources. 

Date: March 26, 2024. 

Time: 9:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 89, No. 43 / Monday, March 4, 2024 / Notices 15601 

1Prior to 2002, the NSDUH was referred to as the 

National Household Survey on Drug Abuse 

(NHSDA). 

Contact Person: Ian Frederick Thorpe, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 903K, 

Bethesda, MD 20892, (301) 480–8662, 

ian.thorpe@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Alzheimer’s 

Disease and Traumatic Brain Injury. 

Date: March 26–27, 2024. 

Time: 9:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Roger Alan Bannister, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 1010–D, 

Bethesda, MD 20892, (301) 435–1042, 

bannisterra@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Drug 

Discovery and Molecular Pharmacology. 

Date: March 26, 2024. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Victoria Martinez Virador, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 594–4703, victoria.virador@

nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: AIDS and AIDS-Related Research. 

Date: March 26, 2024. 

Time: 10:30 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Alok Mulky, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4203, 

Bethesda, MD 20892, (301) 435–3566, 

mulkya@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: February 27, 2024. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–04447 Filed 3–1–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Agency Information Collection 

Activities: Proposed Collection; 

Comment Request 

In compliance with section 

3506(c)(2)(A) of the Paperwork 

Reduction Act of 1995 concerning 

opportunity for public comment on 

proposed collections of information, the 

Substance Abuse and Mental Health 

Services Administration (SAMHSA) 

will publish periodic summaries of 

proposed projects. To request more 

information on the proposed projects or 

to obtain a copy of the information 

collection plans, call the SAMHSA 

Reports Clearance Officer on (240) 276– 

0361. 

Comments are invited on: (a) Whether 

the proposed collections of information 

are necessary for the proper 

performance of the functions of the 

agency, including whether the 

information shall have practical utility; 

(b) the accuracy of the agency’s estimate 

of the burden of the proposed collection 

of information; (c) ways to enhance the 

quality, utility, and clarity of the 

information to be collected; (d) ways to 

minimize the burden of the collection of 

information on respondents, including 

through the use of automated collection 

techniques or other forms of information 

technology; (e) of the addition of data 

collection in the U.S. Territories; and (f) 

implications and feedback on proposing 

to change the name of the survey. 

Proposed Project: National Survey on 

Drug Use and Health (OMB No. 0930– 

0110) 

The National Survey on Drug Use and 

Health (NSDUH) is a survey of the U.S. 

civilian, non-institutionalized 

population aged 12 years old or older. 

The data are used to provide estimates 

of substance use and mental illness at 

the national, state, and substate levels. 

NSDUH data also help to identify the 

extent of substance use and mental 

illness among different subgroups, 

estimate trends over time, and 

determine the need for treatment 

services. The results are used by 

SAMHSA, the Office of National Drug 

Control Policy (ONDCP), Federal 

Government agencies, and other 

organizations and researchers to 

establish policy, direct program 

activities, and better allocate resources. 

For the 2025 NSDUH, SAMHSA is 

proposing to change the name of the 

study to the National Household Survey 

on Behavioral Health (NHSBH) to 

emphasize the inclusion of the longstanding mental health-related survey 

elements and to clarify for key 

stakeholders the full content of the 

survey’s questions and data. The 

proposed name change will facilitate 

participant, researcher, and public 

understanding that the NSDUH is 

focused on both drug use but also 

mental health. The current name of the 

survey does not specifically capture 

questionnaire items across substance 

use and mental health, both separately 

and as co-occurring conditions. In 

addition, the name change will better 

align the survey with SAMHSA’s 

mission. 

The survey’s name is currently well 

recognized by those in the community, 

states, and academia, and this 

recognition comes from the quality of 

the information provided. The 

continuing excellence of the 

information provided is anticipated to 

re-establish the recognition of the 

survey with the new name. It is 

anticipated that changing the name of 

the survey will highlight mental health 

components. 

SAMHSA is committed to addressing 

any concerns with a name change that 

may lead to confusion and/or 

misperception among some stakeholders 

and the general public, which could 

affect participation in the survey, 

misinterpretation of changes with the 

survey’s content or purpose, or 

difficulty locating the pertinent 

information about the study’s results. 

Nonetheless, these potential stakeholder 

responses and challenges will be 

addressed by emphasizing the 

significance of a name that reflects the 

complete content of the survey. A new 

name may also facilitate discussions on 

substance use and co-occurring mental 

health disorders. 

Efforts will be made to promote, 

market, and educate about the quality 

and applicability of the results. These 

efforts may spark renewed interest in 

the survey and the uptake of the results 

in publications and reports. 

As with all NSDUH/NHSDA 1 surveys 

conducted since 1999, the sample size 

of the NSDUH main study for 2025 will 

be sufficient to permit prevalence 

estimates for each of the fifty states and 

the District of Columbia. The total 

annual burden estimate for the NSDUH 

main study is shown below in Table 1. 


khammond on DSKJM1Z7X2PROD with NOTICES